Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug Entresto. CEO Vas Narasimhan discussed the company's strategic focus on navigating significant patent expiries in the first half of the year, followed by a growth phase in the second half fueled by investments in the pipeline and new product launches.
He speaks with Romaine Bostick & Katie Greifeld on "The Close." More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't
miss any videos from Bloomberg Markets & Finance Visit for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on Connect with
Bloomberg Business on TikTok Reddit More from Bloomberg Bloomberg Radio Bloomberg Surveillance Bloomberg Politics Bloomberg Originals Watch more on Bloomberg Technology Bloomberg Originals Bloomberg Quicktake Bloomberg Espanol Bloomberg Podcasts
The BriefWire